ArticleScientific reports2026
RhoA accelerates atherosclerosis progression by interacting with Hspa5.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GRP78 in human diseases: From molecular chaperone to therapeutic target.Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
RhoA has been demonstrated to play a role in atherosclerosis (AS); however, its regulatory mechanisms remain poorly characterized. This study aimed to investigate the function of RhoA in AS and elucidate its underlying mechanisms. An AS mouse model was established via a high-fat diet, and the role of RhoA was assessed by administering adeno-associated viruses. Mouse aortic vascular smooth muscle cells (MOVAS) were exposed to oxidized low-density lipoprotein (ox-LDL), and cellular phenotypes were analyzed using cell counting kit-8 assays, Transwell migration assays, transmission electron microscopy, and western blotting. The interaction between RhoA and Hspa5 was investigated through bioinformatic analysis, co-immunoprecipitation, and immunofluorescence. Results revealed that RhoA was highly upregulated in AS mice and predominantly localized in the smooth muscle layer of the aortic root. Knockdown of RhoA or inhibit its activity suppressed the viability, migration, invasion, and mitophagy of ox-LDL-treated MOVAS cells in vitro, and reduced plaque formation and inflammatory responses in AS mice. Furthermore, Hspa5 was found to interact with RhoA, with its expression positively correlated to RhoA levels. Overexpression of Hspa5 counteracted the inhibitory effects of RhoA silencing on cellular behaviors in ox-LDL-stimulated cells in vitro and plaque lesions and inflammation responses in vivo. Collectively, RhoA promotes vascular smooth muscle cell migration, invasion, and mitophagy via interaction with Hspa5, thereby exacerbating AS progression. These findings highlight RhoA as a potential therapeutic target for AS treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.